Abstract
The nonstructural protein 3 (NS3) of hepatitis C virus contains a protease domain at its amino terminus and RNA helicase domain at its carboxyl terminus. To identify optimal NS3 protein for developing screening assays, we expressed full-length NS3 protease/helicase and helicase domains from both HCV type 1a (H77 strain) and 1b (Con1 strain), using either E. coli or baculovirus expression systems. Our studies showed that the full-length NS3 proteins, either with or without the presence of the NS4A domain, from either strains were at least 10-fold more efficient than the corresponding helicase domains in unwinding partial duplex RNA substrates. These findings provide a rationale for the use of full-length NS3 in high throughput screening assays to identify potent small molecule inhibitors of this important target of HCV.
Keywords: hcv, ns, protease domain, helicase domain, coli, baculovirus, unwinding activity
Protein & Peptide Letters
Title: The RNA-Unwinding Activity of Hepatitis C Virus Non-Structural Protein 3 (NS3) Is Positively Modulated by Its Protease Domain
Volume: 12 Issue: 4
Author(s): Baohua Gu, Cynthia M. Pruss, Adam T. Gates and Sanjay S. Khandekar
Affiliation:
Keywords: hcv, ns, protease domain, helicase domain, coli, baculovirus, unwinding activity
Abstract: The nonstructural protein 3 (NS3) of hepatitis C virus contains a protease domain at its amino terminus and RNA helicase domain at its carboxyl terminus. To identify optimal NS3 protein for developing screening assays, we expressed full-length NS3 protease/helicase and helicase domains from both HCV type 1a (H77 strain) and 1b (Con1 strain), using either E. coli or baculovirus expression systems. Our studies showed that the full-length NS3 proteins, either with or without the presence of the NS4A domain, from either strains were at least 10-fold more efficient than the corresponding helicase domains in unwinding partial duplex RNA substrates. These findings provide a rationale for the use of full-length NS3 in high throughput screening assays to identify potent small molecule inhibitors of this important target of HCV.
Export Options
About this article
Cite this article as:
Gu Baohua, Pruss M. Cynthia, Gates T. Adam and Khandekar S. Sanjay, The RNA-Unwinding Activity of Hepatitis C Virus Non-Structural Protein 3 (NS3) Is Positively Modulated by Its Protease Domain, Protein & Peptide Letters 2005; 12 (4) . https://dx.doi.org/10.2174/0929866053765716
DOI https://dx.doi.org/10.2174/0929866053765716 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Herpesvirus Saimiri-Based Gene Delivery Vectors
Current Gene Therapy Pluripotent Stem Cells for Livestock Health and Production
Current Stem Cell Research & Therapy Clinical Significance of Breast Cancer Resistance Protein/ABCG2 in the Management of Malignancy
Clinical Cancer Drugs Indoor Dust Levels of Perfluoroalkyl Substances (PFASs) and the Role of Ingestion as an Exposure Pathway: A Review
Current Organic Chemistry Patents Related to Cancer Stem Cell Research
Recent Patents on DNA & Gene Sequences The Development of Pro-Apoptotic Cancer Therapeutics
Mini-Reviews in Medicinal Chemistry Recent Advances in Asialoglycoprotein Receptor and Glycyrrhetinic Acid Receptor-Mediated and/or pH-Responsive Hepatocellular Carcinoma- Targeted Drug Delivery
Current Medicinal Chemistry Pentacyclic Triterpenoids and Their Saponins with Apoptosis-Inducing Activity
Current Topics in Medicinal Chemistry Beyond Single Pathway Inhibition: MEK Inhibitors as a Platform for the Development of Pharmacological Combinations with Synergistic Anti-Leukemic Effects
Current Pharmaceutical Design Pharmaceutical Targeting of the Brain
Current Pharmaceutical Design Role of Natural Phenolic Compounds in Cancer Chemoprevention via Regulation of the Cell Cycle
Current Pharmaceutical Biotechnology Medicinal Compound Celastrol As a Potential Clinical Anticancer Drug: Lessons Learned From Preclinical Studies
Clinical Cancer Drugs Determinants of Treatment Outcomes for Hepatitis C Infection and the Path to Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Recent Advances in the Therapeutic Perspectives of Nutlin-3
Current Pharmaceutical Design HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery Knemometry for Assessment of Growth Suppressive Effects of Exogenous Glucocorticoids
Current Pediatric Reviews Role of the Wnt/β-Catenin Pathway in the Pathogenesis of Alcoholic Liver Disease
Current Molecular Pharmacology The ATP-driven Hsp60 Machinery: Biological and Clinical Implications
Current Immunology Reviews (Discontinued) Nanotechnology Based Approach for Hepatocellular Carcinoma Targeting
Current Drug Targets Metabolism and Mechanism of Human Cytochrome P450 Enzyme 1A2
Current Drug Metabolism